14
Participants
Start Date
July 31, 2007
Primary Completion Date
March 31, 2012
Study Completion Date
August 31, 2014
Drug: 5-FU
Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
Drug: Oxaliplatin
40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
UPMC Cancer Centers Network, Pittsburgh
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
David Bartlett
OTHER